BIIB
Biogen Inc (BIIB) Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Inc (BIIB) Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Inc (BIIB) Biogen Announces Board Chair Transition
Biogen Inc (NASDAQ: BIIB) FY 2026 Management Update
Biogen Inc (BIIB) Sec Form 10K
Biogen Inc (NASDAQ: BIIB) Sec Form 10K
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Shares Rise on Q4 Earnings Beat Despite Lower Revenue Outlook
Shares of Biogen Inc (BIIB) rose 8.53% to $201.18 at close on Friday following the release of fourth-quarter and full-year…